Release Summary

Longer Term Follow-Up Data with Merck’s KEYTRUDA in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO

Merck